Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 64.7% from a year ago
Total assets stood at $497.6M at the end of Q1 FY2026, up 64.7% from a year earlier and down 2.9% from the prior quarter. Over 3 fiscal years it compounded at +153.1% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +64.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 512.43M USD
- Year-over-year change
- +62.7%
- 3-year CAGR
- +153.1%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 512.43M | +62.7% |
| FY2024 | 2024-12-31 | 314.93M | +102.6% |
| FY2023 | 2023-12-31 | 155.42M | +391.8% |
| FY2022 | 2022-12-31 | 31.6M | — |
Total Assets vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total assets of $497.6M is the 4th highest of the 10 companies compared; the peer median is $393.48M.
- Its year-over-year change of +64.7% is the 4th highest of 10, against a peer median of +53.8%.
- Over three fiscal years its annual growth of +153.1% compares with a peer median of +53.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $1.79B | +34.8% | +38.6% | |
| Sep 2026 | $1.31B | +231.0% | +101.2% | |
| Jun 2026 | $761.45M | +19.0% | +27.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $497.6M | +64.7% | +153.1% |
| Mar 2026 | $418.79M | +275.4% | +130.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $393.48M | +1944.3% | +144.2% |
| Mar 2026 | $276.26M | +60.7% | +53.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $261.35M | +31.8% | +76.1% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.88M | -40.1% | -23.5% |
| Mar 2026 | $36.14M | +53.8% | -1.4% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — |
| Peer median (excluding RAPP) | $393.48M | +53.8% | +53.7% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.